Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

The maternal embryonic leucine zipper kinase as a therapeutic target in castration-resistant prostate cancer

FY 2016-17

Summary
The discovery that advanced metastatic castration-resistant prostate cancer remains driven by androgen receptor signaling has ushered the development and clinical integration of highly effective androgen receptor pathway inhibitors, most notably enzalutamide. These agents have undoubtedly benefited patients with castration-resistant prostate cancer, but are merely palliative as resistance rapidly emerges. A large proportion of these resistant patients present with elevated expression of MELK, a kinase that is implicated in tumor survival. Our lab will utilize genome editing technology to investigate the role of MELK in resistance to first-line prostate cancer therapies and demonstrate the utility of targeting MELK in castration-resistant prostate cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367163
Name
Johnson Fraser
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The maternal embryonic leucine zipper kinase as a therapeutic target in castration-resistant prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Androgen Receptor; Cancer Stem Cells; Crispr; Enzalutamide; Kinase; Prostate Cancer; Therapeutic Resistance
Abstract
The discovery that advanced metastatic castration-resistant prostate cancer remains driven by androgen receptor signaling has ushered the development and clinical integration of highly effective androgen receptor pathway inhibitors, most notably enzalutamide. These agents have undoubtedly benefited patients with castration-resistant prostate cancer, but are merely palliative as resistance rapidly emerges. A large proportion of these resistant patients present with elevated expression of MELK, a kinase that is implicated in tumor survival. Our lab will utilize genome editing technology to investigate the role of MELK in resistance to first-line prostate cancer therapies and demonstrate the utility of targeting MELK in castration-resistant prostate cancer.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Johnson, Fraser
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~